Categories: U.S. Policy and Funding
Categories: Seeyasoon, HIV/AIDS
IDSA Leads Support for READI Act (PDF)
IDSA and over forty other organizations representing healthcare providers, hospitals, pharmacists, scientists and microbiologists, industry, public health experts, patients and advocates expressed support for the Reinvigorating Antibiotic and Diagnostic Innovation (READI) Act.
IDSA Statement on the Repeal of the Prevention and Public Health Fund
The Infectious Diseases Society of America (IDSA) is deeply concerned that the proposed American Health Care Act under consideration in Congress would repeal the Prevention and Public Health Fund.
Evaluation of Safe Consumption Sites in the U.S.
The Infectious Diseases Society of America and the HIV Medicine Association strongly support a public health approach to addressing the opioid epidemic to reduce the spread of infections and to engage individuals who inject drugs in substance use treatment and other healthcare services.
IDSA Leads Support for Robust Federal Public Health and Biomedical Research Workforce (PDF)
IDSA led over 150 groups in a letter to President Trump in support of a robust federal public health and biomedical research workforce.
IDSA Statement on WHO Priority Antibiotic-Resistant Pathogen List
The Infectious Diseases Society of America welcomes the announcement from the World Health Organization of its “priority pathogens” list to guide and promote antibiotic research and development. We call upon United States policy makers and international leaders to commit the resources necessary to realize the goals of this list.
IDSA Highlights Pressing ID Policy Issues for New HHS Secretary (PDF)
IDSA outlines a number of pressing ID policy priorities for new HHS Secretary Dr. Tom Price, including antimicrobial resistance, domestic and global public health programs, infrastructure, and preparedness, biomedical research and innovation, and ID physician workforce issues.
IDSA Releases Core Principles for Antibacterial Drug Pathway (PDF)
IDSA and other groups outline a proposed new law to create a limited population antibacterial drug (LPAD) pathway.
IDSA Statement on Executive Order on Immigrant and Refugee Travel to U.S.
Infectious diseases do not respect national borders, and success in fighting them requires a global response. Broad international collaboration is critical to our ability to identify, track and respond to emerging infectious diseases.
1 of 8
FDA approves two hepatitis C drugs for pediatric patients
The U.S. Food and Drug Administration today approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Harvoni and Sovaldi were previously approved to treat HCV in adults.
CDC: About 1 in 10 U.S. pregnant women with confirmed Zika infection had a fetus or baby with birth defects in 2016
Of the 250 pregnant women who had confirmed Zika infection in 2016, 24 – or about 1 in 10 of them – had a fetus or baby with Zika-related birth defects, according to a new Vital Signs report from the Centers for Disease Control and Prevention (CDC). This report is the first to provide the analysis of a subgroup of pregnant women in the U.S. with clear, confirmed test results of Zika virus infection.
CDC Updates Specimen Collection, Shipping, and Testing Guidance for Suspected Acute Flaccid Myelitis (AFM) Cases
Despite extensive pathogen-specific testing of many specimens since 2014, CDC and others have not identified an etiology for the AFM cases. Therefore, CDC will no longer perform clinical diagnostics for enteroviruses or metagenomic sequencing on specimens collected from suspect cases of AFM.
Information for Healthcare Personnel Potentially Exposed to Hepatitis C Virus (HCV): Recommended Testing and Follow-up
Exposure to viral hepatitis has long been recognized as an occupational risk for healthcare personnel, with recommendations previously established for the management of occupational exposures to hepatitis C virus (HCV).
CDC adds 4 countries to interim travel guidance related to Zika virus
CDC is working with other public health officials to monitor for ongoing spread of Zika virus. Today, CDC posted a Zika virus travel notice for Angola, Guinea-Bissau, Maldives and Solomon Islands. .
New FDA Drug Safety Communication on chlorhexidine gluconate - Drug Information Update
FDA Drug Safety Communication on chlorhexidine gluconate- Drug Information
FDA MedWatch - ED-3490TK Video Duodenoscope by Pentax: FDA Safety Communication - UPDATE
FDA MedWatch - Duodenoscopes by Fujifilm Medical Systems: Safety Communication - Certain Older Models Removed From Clinical Use
Read More >>
IDSA strongly supports the Reinvigorating Antibiotic and Diagnostic Innovation (READI) Act, H.R. 1840, introduced yesterday by Representatives Erik Paulsen (R-MN) and Mike Thompson (D-CA), which would provide a new tax credit, modeled after the Orphan Drug tax credit, for new antibiotics that treat a serious or life threatening infection and address an unmet medical need and for new rapid diagnostic tests.
The Infectious Diseases Society of America (IDSA) and the HIV Medicine Association (HIVMA) are alarmed by the Trump administration’s proposed cuts to FY2017 funding for the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC) public health preparedness and response grants, global and domestic HIV and TB efforts at the CDC, and global health programs at the United States Agency for International Development (USAID) and the State Department.
The Infectious Diseases Society of America (IDSA) is deeply troubled that the budget blueprint released today by the Trump administration proposes a $5.8 billion cut to the National Institutes of Health (NIH) and cuts to the Health and Human Services (HHS) emergency preparedness programs.
Diseases Society of America (IDSA) is deeply concerned that the proposed
American Health Care Act under consideration in Congress would repeal the
Prevention and Public Health Fund.
A new CID study suggests that the current vaccine is most effective at preventing postherpetic neuralgia and cases requiring hospitalization.
A JID study suggests the high-dose flu vaccine was more effective at preventing deaths among seniors than the standard-dose vaccine during a more severe flu season.
New IDSA Guideline on Ventriculitis and MeningitisFederal Government Transition UpdatesJournal Club
1 of 7
1300 Wilson Boulevard Suite 300 Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2017 Infectious Diseases Society of America